D.R. Horton’s Home Prices Hit 2021 Lows, Down 12% in...
Key Takeaways D.R. Horton’s average home selling price has fallen over 12% since its 2022 peak, returning to levels last seen in 2021, currently averaging around $305,000. The price decline...
Key Takeaways D.R. Horton’s average home selling price has fallen over 12% since its 2022 peak, returning to levels last seen in 2021, currently averaging around $305,000. The price decline...
Key Takeaways A proposal to eliminate capital gains tax on residential property sales in the United States is being discussed, a move that could significantly alter the housing market and...
Key Takeaways xAI is reportedly seeking an additional $10 billion to $12 billion in funding, on top of its recent $6 billion Series B raise, to fuel a massive expansion...
The possibility of a high-level meeting between US President Donald Trump and Chinese President Xi Jinping in the coming months has emerged as a focal point for global markets, with...
Key Takeaways For the first time in over a decade, Lockheed Martin reported an unprofitable quarter (Q2 2025) in two of its largest divisions: Aeronautics and Missiles and Fire Control....
Key Takeaways AMD’s Instinct MI300 series has driven significant data centre growth, surpassing $1 billion in cumulative sales within two quarters of its launch. Wall Street projects AMD’s AI GPU...
Labrador Iron Ore Royalty Corporation offers investors a unique exposure to iron ore prices without the operational headaches, thanks to its stake and royalties from the Iron Ore Company of...
Key Takeaways Rocket Lab is emerging as a credible challenger to SpaceX for high-value US defence contracts, particularly the “Golden Dome” missile defence programme. The US government appears to be...
Key Takeaways Intuitive Machines (LUNR) is positioned as a key beneficiary of the burgeoning lunar economy, driven by geopolitical competition between the US and China and the push for a...
MoonLake Immunotherapeutics offers a noteworthy investment prospect in the expanding immunology sector. With a strong buy recommendation and a price target of $61, the company's robust cash position and advanced...
CTA Content